✉ Email this page to a colleague
« Back to Dashboard
Esreboxetine is an investigational drug.
There have been 4 clinical trials for Esreboxetine. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2009.
The most common disease conditions in clinical trials are Fibromyalgia, Myofascial Pain Syndromes, and [disabled in preview]. The leading clinical trial sponsors are Pfizer and [disabled in preview].
Recent Clinical Trials for Esreboxetine
|Maintenance of Efficacy.||Pfizer||Phase 3|
|Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine||Pfizer||Phase 1|
|Phase 1 Thorough QT (TQT) Study in Young Healthy Volunteers||Pfizer||Phase 1|